Most retatrutide "results" content you'll find online is either trial averages (accurate but abstract) or individual anecdotes (vivid but unrepresentative). This page blends both — trial numbers for the anchor, community-reported patterns for texture.
The weight-loss timeline
These numbers are averages. Your actual trajectory will depend on starting weight, starting dose, escalation speed, food environment, protein intake, sleep, and medication consistency. A 240-pound person at 50% fat mass will lose faster per week than a 170-pound person at 30% fat mass, even on the same dose.
Month-by-month: what to expect
Month 1 (0.5 mg weekly)
The starter dose is low enough that GI side effects are mild. Appetite reduction begins within the first week but is subtle — most people describe it as "reduced interest in food" rather than dramatic satiety. Expected weight loss: 2–4%, largely initial water shifts as dietary patterns adjust.
Month 2 (1 mg weekly)
First meaningful dose escalation. Nausea peaks briefly in the first week of this new rung. Appetite suppression becomes more noticeable — many users naturally skip snacks or reduce portion sizes without conscious effort. Expected loss: cumulative 5–7%.
Month 3 (2 mg weekly)
Weight loss velocity increases. Clothing fits differently. Some users hit an initial "novelty" plateau as their body adapts to reduced caloric intake; breaking it usually means adding protein and resistance training. Cumulative loss: 8–10%.
Month 4–5 (4 mg weekly)
The dose level where Phase 2 showed a major efficacy bump. Appetite suppression is strong, and some users report forgetting to eat. Hydration becomes critical (nausea worsens when thirsty). Cumulative loss: 12–15%.
Month 6–9 (8 mg or maintenance)
Weight loss continues but at a slower per-week pace as body fat percentage drops. This is the window where muscle preservation matters most — adequate protein and resistance training prevent excessive lean loss. Cumulative loss: 18–22%.
Month 10–12 (12 mg or stable maintenance)
Peak weight loss rates. Some users choose to stop escalating at 8 mg; others continue to 12 mg. Cumulative loss: 22–24%.
Beyond 12 months
Phase 2 ended at 48 weeks, so Phase 3 data are still being collected beyond that point. Tirzepatide's SURMOUNT-1 showed continued loss through week 72, then plateau. Retatrutide's trajectory likely mirrors this pattern, with total loss potentially reaching 25–27% at 72 weeks.
Retatrutide reviews from the peptide community
Reddit's r/Retatrutide and r/Peptides document thousands of self-experiments. Common themes:
- "Stalls at month 3–4 are normal." Users report a cumulative 10–12% loss, then a 2–3 week stall before continuing. Usually resolves with the next dose escalation.
- "Hydration is everything." Nausea and headaches almost always correlate with inadequate fluid intake.
- "Injection site sting is real." Bringing the vial to room temperature before drawing reduces it substantially.
- "Food noise disappears." The most commonly cited subjective effect — the "always thinking about food" mental loop quiets down.
- "Protein or you'll lose muscle." Users who aim for 1.2+ g/kg protein preserve more lean mass than those who eat-what-they-feel-like on reduced appetite.
Retatrutide before and after: the realistic picture
Dramatic before-and-after photos circulate, but the average experience is less cinematic. A person starting at BMI 37 losing 24% over a year goes from ~240 lb to ~183 lb — meaningful, health-transforming, but not a magazine-cover transformation. Two-year follow-up (if maintained) can push further, but maintenance on most GLP-1 drugs requires continued dosing — stopping is followed by partial weight regain in most patients.
Retatrutide reddit consensus: the unfiltered version
Reddit is not pharmacology, but patterns from self-reported experience:
- Best results come from combining retatrutide with moderate calorie awareness (not extreme restriction) and resistance training.
- Side-effect severity is more correlated with escalation speed than with absolute dose.
- Consistent injection day and site rotation reduce "bad week" variance.
- Users who microdose (2–4 mg maintenance) report 12–18% loss — enough for most health goals, with minimal side effects.
- Research peptide quality is the single biggest source of unexpectedly-weak results. Users who verify batch potency rarely report "it stopped working."
Plateaus, stalls, and how to break them
Weight-loss plateaus on any GLP-1 drug follow a few patterns:
- The 3-week stall at 8–10% loss. Adaptive thermogenesis + loose weekends. Tighten protein and hydration for a week; usually resolves.
- The 5-month plateau at 15–17%. Maintenance dose has saturated appetite suppression; body adapted. Consider escalation or accept current loss.
- The 9-month plateau. Often the true physiological endpoint for that dose. Going higher (8 → 12 mg) can add 2–4 percentage points; not always worth the GI cost.